Journal Logo


FC29 Electrochemotherapy (ECT) as a new anticancer therapeutic modality: the Hellenic Group of ECT (HeGECT) experience

Kyrgias, G.a b; Mosa, E.a; Filopoulos, E.a; Kokalis, G.a; Lepouras, A.c; Zafiriou, E.b; Papamanthos, M.b; Theodorou, K.b; Kappas, K.b; Skarlatos, J.a

Author Information
doi: 10.1097/01.cmr.0000382831.74608.bc
  • Free

Introduction ECT is based on the local delivery of electric pulses that causes transient permeabilisation of the cell membrane, facilitating the intracellular delivery of chemotherapeutic drugs, otherwise not permitted by the integrity of the membrane. ECT was first introduced at the Institute Gustave Roussy in France (1990 - with bleomycin) and at the Institute of Oncology, Ljubljana, Slovenia (1994 - with cisplatin). Today we find more than 300 records in PubMed search for more than 1000 patients treated all over the world, Greece included.

Methods In the framework of the ESOPE-EU project, the standard operational procedures are well defined and certified with the participation of four leading European Cancer Centers.

Results The aim of this presentation is to focus on the ECT Treatment clinical experience gathered from 44 patients treated and 64 applications performed by the Hellenic Group of ECT (HeGECT).

Conclusion Electrochemotherapy (ECT) is a highly efficient and safe new anticancer therapeutic modality, useful predominantly in cutaneous and subcutaneous tumor nodules of multiple origins and histological types.

© 2010 Lippincott Williams & Wilkins, Inc.